Loading…
← CockpitCompetitor Analysis › ZOTA.NS Zota Health Care Ltd.Open in the cockpit ↗

Zota Health Care Ltd.ZOTA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum strong 76
Mkt cap
$427M
US dollars, full cap
Free float
38%
of shares outstanding
$/day
$730,202
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-20.4 pp
WACC 10.7%
Hurdle
n/a
no reverse DCF
Next earnings
84 days
10 Feb 2027
Close · INR₹1,314
1D+1.9%
1W-0.7%
1M-3.3%
3M+21.1%
6M+9.1%
YTD-14.9%
1Y-14.2%
ATR %4.4%
Beta0.90
52w lowhigh24.4% off high

What Zota Health Care does

Employees: 635

Zota Health Care at a glance

Size Zota Health Care (ZOTA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $427M, the 917th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹1,314 on 18 Nov 2026.

Performance Over six months the shares gained 9.1%, against -25.4% for the median peer and +3.8% for the India market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 69.0% over the last twelve months (peer median +5.5%); the operating margin is -15.6% (peer median 2.6%).

Valuation It trades at 6.2× enterprise value to sales against a peer median of 2.9× (6th most expensive of 20).

Capital Return on invested capital runs 20.4 points below its cost of capital (10.7% WACC).

Next results Next results expected around 10 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026ZOTA.NS 109Peer median 77
Six months, rebased to 100: Zota Health Care against the median of its 20 peers (local-currency closes).

Zota Health Care financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹6.79B₹5.39B₹2.92B₹1.80B₹1.39B
Revenue growth—+84%+62%+29%—
Gross profit₹733M₹605M₹221M₹310M₹305M
EBITDA-₹2.75M₹186M-₹49.7M₹76.7M₹74.9M
Net income-₹1.13B-₹739M-₹564M-₹143M-₹57.7M
Free cash flown/a-₹2.05B-₹949M-₹218M-₹137M
Capital expendituren/a₹1.26B₹460M₹167M₹125M
Total debt₹2.71B₹2.70B₹1.40B₹953M₹451M

Quarterly statements and history in the cockpit →

Zota Health Care competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%OVID6006130484100029234114601089001060PHATTVGN6031396881176050776881360027280005180007880029000024627871RPGLIFEZOTA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Zota Health Care is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%+6,000%0×100×200×OVID6006130484100029230005187871ZOTA.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zota Health Care is the large dot.

Zota Health Care competitors and peer comparison

How Zota Health Care compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zota Health Care against its 20 peers (data as of 18 Nov 2026)
MeasureZOTA.NSPeer medianRank in peer set
1-month return-3.3%-13.0%highest of 21
6-month return+9.1%-25.4%3rd highest of 21
Distance from 52-week high-24.4%-46.9%3rd highest of 21
Revenue growth (TTM)+69.0%+5.5%4th highest of 20
Operating margin-15.6%2.6%7th lowest of 20
EV / Sales6.2×2.9×6th most expensive of 20
ROIC minus cost of capital-20.4 pp-4.8 pp5th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Zota Health Care ZOTA.NSIndia$427M+9%+69%-16%6.2×n/an/a
Ovid Therapeutics OVIDUnited States$427M-5%-78%-4,700%208.3×n/an/a
Shanghai Shenqi Pharmaceutical Investment Management 600613.SSChina$427M+4%-4%3%1.2×10.6%+1.4%
Hyundai Bioscience 048410.KSSouth Korea$424M-50%+78%-580%164.0×n/an/a
Zhuhai Rundu Pharmaceutical 002923.SZChina$430M-30%+14%5%2.2×1.4%-1.3%
Synmosa Biopharma 4114.TWOTaiwan$423M-1%+21%10%2.2×5.4%+15.3%
Beijing Foyou Pharma 601089.SSChina$423M-27%+5%10%0.2×n/an/a
JW Pharmaceutical 001060.KSSouth Korea$423M-26%+9%13%0.7×-15.4%+7.2%
Phathom Pharmaceuticals PHATUnited States$431M-55%+87%-9%2.9×n/an/a
Tevogen TVGNUnited States$422M-38%n/an/an/an/an/a
Shaanxi Kanghui Pharmaceutical Co 603139.SSChina$421M-31%+1%-39%7.1×n/an/a
Cheng Du Sheng Nuo Biotec 688117.SSChina$433M-48%+51%27%3.4×-0.2%+14.5%
Zhejiang Huakang Pharmaceutical 605077.SSChina$433M-47%+35%4%1.1×n/an/a
Kexing Biopharm 688136.SSChina$433M-42%-14%-12%2.9×n/an/a
Teyi Pharmaceutical 002728.SZChina$419M-12%-7%7%3.2×24.4%+8.0%
Jiangsu Sihuan Bioengineering 000518.SZChina$437M-8%-17%-28%10.6×n/an/a
PKU Healthcare 000788.SZChina$437M-12%-49%5%2.1×-5.6%-5.6%
Harbin Medisan Pharmaceutical 002900.SZChina$437M-16%-5%-29%4.2×n/an/a
Cachet Pharmaceutical 002462.SZChina$441M-25%-14%0%0.2×-9.9%-3.4%
Elixiron Immunotherapeutics (Cayman) 7871.TWOTaiwan$412M+64%+6,162%-194%119.7×n/an/a
RPG Life Sciences RPGLIFE.NSIndia$443M+10%+15%17%5.3×n/an/a

Questions

Which companies are Zota Health Care's closest peers?
The cockpit's peer set: Ovid Therapeutics (OVID), Shanghai Shenqi Pharmaceutical Investment Management (600613.SS), Hyundai Bioscience (048410.KS), Zhuhai Rundu Pharmaceutical (002923.SZ), Synmosa Biopharma (4114.TWO), Beijing Foyou Pharma (601089.SS), JW Pharmaceutical (001060.KS), Phathom Pharmaceuticals (PHAT).
Is Zota Health Care expensive compared with its peers?
On ev / sales it trades at 6.2× against a peer median of 2.9×, 6th most expensive of 20 in its peer set.
How has Zota Health Care stock performed?
Over six months to 18 Nov 2026 the shares returned +9.1% against -25.4% for the median peer; over one year -14.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.